Pimecrolimus is exclusively metabolised by CYP 450 3A4.
Potential interactions between Elidel 1% cream and other drugs have not been systematically evaluated. Based on its minimal extent of absorption, interactions of Elidel 1% cream with systemically administered drugs are unlikely to occur (see Pharmacology: PHARMACOKINETICS under Actions).
A study that included 79 infants treated for up to 2 years showed that treatment with Elidel 1% Cream did not interfere with the protective immune response to childhood vaccinations. Application of Elidel 1% cream to vaccination sites, as long as local reactions persist, was not studied and is therefore not recommended.
Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other topical medicinal products.
Emollients can be applied together with Elidel 1% cream (see DOSAGE & ADMINISTRATION).